

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

  
**VISEN Pharmaceuticals**  
**维昇药业**  
*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 2561)**

**(1) POLL RESULTS OF THE ANNUAL GENERAL MEETING  
HELD ON 27 JUNE 2025;**  
**(2) RETIREMENT OF NON-EXECUTIVE DIRECTORS;**  
**(3) CHANGE OF CHAIRMAN OF THE BOARD; AND**  
**(4) CHANGE OF COMPOSITION OF NOMINATION COMMITTEE**

At the annual general meeting (the “AGM”) of VISEN Pharmaceuticals (the “Company”) held on 27 June 2025, all the proposed resolutions as set out in the notice of the AGM dated 30 April 2025 and the supplemental notice of AGM dated 12 June 2025, respectively, were taken by poll. The poll results are as follows:

Ordinary Resolutions		Number of Votes (%) <sup>(Note (a))</sup>	
		For	Against
1.	To receive the audited consolidated financial statements of the Company and the reports of the directors (the “Director(s)”) and auditors of the Company for the year ended 31 December 2024.	89,262,028 (100.000000%)	0 (0.000000%)
2(a).	To re-elect Mr. LU An-Bang as an executive Director of the Company.	89,262,028 (100.000000%)	0 (0.000000%)
2(b).	To re-elect Mr. FU Shan as a non-executive Director of the Company.	89,262,028 (100.000000%)	0 (0.000000%)
2(c).	To re-elect Mr. Michael J. CHANG as a non-executive Director of the Company.	89,262,028 (100.000000%)	0 (0.000000%)
2(d).	To re-elect Mr. CAO Yibo as a non-executive Director of the Company.	89,262,028 (100.000000%)	0 (0.000000%)
2(e).	To re-elect Dr. YAO Zhengbin (Bing) as an independent non-executive Director of the Company.	89,262,028 (100.000000%)	0 (0.000000%)
2(f).	To re-elect Mr. CHAN Peng Kuan as an independent non-executive Director of the Company.	89,262,028 (100.000000%)	0 (0.000000%)
2(g).	To re-elect Ms. NI Hong as an independent non-executive Director of the Company.	89,262,028 (100.000000%)	0 (0.000000%)
2(h).	To authorize the board of Directors of the Company to fix the respective Director’s remuneration.	89,262,028 (100.000000%)	0 (0.000000%)

Ordinary Resolutions		Number of Votes (%) <sup>(Note (a))</sup>	
		For	Against
3.	To re-appoint Ernst & Young as auditor of the Company and to authorize the board of Directors to fix their remuneration.	89,262,028 (100.000000%)	0 (0.000000%)
4.	To give a general mandate to the Directors to repurchase shares of the Company not exceeding 10% of the total number of issued shares of the Company (excluding any treasury Shares) as at the date of passing of this resolution.	89,262,028 (100.000000%)	0 (0.000000%)
5.	To give a general mandate to the Directors to issue, allot and deal with additional shares of the Company not exceeding 20% of the total number of issued shares of the Company (excluding any treasury Shares) as at the date of passing of this resolution.	89,262,028 (100.000000%)	0 (0.000000%)
6.	To extend, conditional upon the passing of resolutions no. 4 and 5, the general mandate granted to the Directors to issue, allot and deal with additional shares in the capital of the Company by the aggregate number of the shares repurchased by the Company.	89,262,028 (100.000000%)	0 (0.000000%)
7.	To generally and unconditionally approve, confirm and ratify the commercial supply framework agreement dated 12 June 2025 entered into between VISEN Pharmaceuticals HK Limited and Ascendis Pharma Europe A/S (the “ <b>Commercial Supply Framework Agreement</b> ”), transaction contemplated thereunder, and the proposed annual caps in relation thereto and to authorize the Directors acting together or by committee, or any Director acting individually, to do all such further acts and things and execute such further documents and take all such steps which in his/her opinion may be necessary, desirable, or expedient to implement and/or give effect to or otherwise in connection with the terms of the Commercial Supply Framework Agreement or the continuing connected transactions contemplated thereby and thereunder.	48,125,664 (100.000000%)	0 (0.000000%)
8.	To approve, confirm and ratify the grant of 435,000 Award Shares (as defined in the circular of the Company dated 12 June 2025), to Mr. LU An-Bang (盧安邦) and to authorize any Directors acting together or by committee, or any Director acting individually to do all such further acts and things and execute such further documents and take all such steps which in his/her opinion may be necessary, desirable, or expedient to implement and/or give effect to or otherwise in connection with the Grant or the transactions contemplated thereby and thereunder.	89,262,028 (100.000000%)	0 (0.000000%)

*Notes:*

- (a) The number and percentage of votes are based on the total number of shares of the Company voted by the shareholders of the Company at the AGM in person or by proxy.
- (b) As all the votes were cast in favour of each of the ordinary resolutions nos. 1 to 8, all the ordinary resolutions at the AGM were duly passed.
- (c) As at the date of the AGM, the total number of shares of the Company in issue was 113,926,864 shares.
- (d) The total number of shares of the Company entitling the holder to attend and vote on the resolutions at the AGM was 113,926,864 shares. Tricor Trust (Hong Kong) Limited, being the trustee holding 3,905,500 unvested RSUs granted under the Equity Incentive Plan; and Tricor Equity Trustee Limited being the trustee holding 5,000,000 Shares underlying RSUs granted to Mr. Lu under the Equity Incentive Plan, was required under Rule 17.05A of the Listing Rules to abstain from voting on matters that require Shareholders' approval under the Listing Rules.
- (e) As disclosed in the Supplemental Circular dated 12 June 2025, under the SFO, Ascendis Pharma A/S is deemed to be interested in a total of 41,136,364 Shares, representing approximately 36.11% of the total number of Shares, and has a material interest in the ordinary resolution no. 7 proposed at the AGM, and therefore Ascendis Pharma A/S, Ascendis Pharma Endocrinology Division, Ascendis Pharma Growth Disorders, Ascendis Pharma Bone Diseases, their respective associates and parties acting in concert are required to abstain from voting for resolution no. 7 at the AGM.  
  
The ordinary resolution no. 8 is subject to approval by the Independent Shareholders, where Mr. Lu, his associates and all core connected persons of the Company are required to abstain from voting for resolution no. 8 at the AGM. Save as disclosed, no Shareholder is required to abstain from voting on the ordinary resolutions to be proposed at the AGM. None of the Shareholders have indicated their intention in the Circular to vote against or abstain from voting in respect of any resolution proposed at the AGM.
- (f) The Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the vote-taking at the AGM.
- (g) Mr. LU An-Bang, Mr. FU Shan, Mr. Michael J. CHANG and Mr. CHAN Peng Kuan attended the AGM in person or by electronics means.

## **RETIREMENT OF NON-EXECUTIVE DIRECTORS**

The Board hereby announces that Mr. Michael Wolff JENSEN and Mr. Jan Møller MIKKELSEN retired from the office at the conclusion of the AGM. Mr. Michael Wolff JENSEN and Mr. Jan Møller MIKKELSEN did not offer themselves for re-election at the AGM in order to strengthen the independence of the Board and ultimately the governance of the Company.

Accordingly, Mr. Michael Wolff JENSEN ceased to be a member of the nomination committee upon the conclusion of the AGM.

Each of Mr. Michael Wolff JENSEN and Mr. Jan Møller MIKKELSEN has confirmed that, in relation to their respective retirement as a non-executive Director, he has no disagreement with the Board and there are no other matters that need to be brought to the attention of the Stock Exchange and/or the Shareholders.

The Board would like to express its sincere gratitude to Mr. Michael Wolff JENSEN and Mr. Jan Møller MIKKELSEN for their valuable contributions to the Company during their tenure of service.

## **CHANGE OF CHAIRMAN OF THE BOARD**

Following the retirement of Mr. Michael Wolff JENSEN as a non-executive Director, he ceased to be the Chairman of the Board. The Board further announces that it has proposed and elected, with effect from the conclusion of the AGM, Mr. FU Shan to succeed as the Chairman of the Board.

## **CHANGE OF COMPOSITION OF NOMINATION COMMITTEE**

Following the retirement of Mr. Michael Wolff JENSEN as a non-executive Director, he ceased to be a member and the Chairman of the nomination committee upon the conclusion of the AGM. The Board further announces that Mr. FU Shan was appointed as a member and the Chairman of the nomination committee of the Company with effect from the conclusion of the AGM.

By order of the Board  
**VISEN Pharmaceuticals**  
**Mr. LU An-Bang**  
*Executive Director and Chief Executive Officer*

Hong Kong, 27 June 2025

*As at the date of this announcement, the board of Directors comprises (i) Mr. LU An-Bang as executive director; (ii) Mr. FU Shan, Mr. Michael J. CHANG and Mr. CAO Yibo as non-executive directors; and (iii) Dr. YAO Zhengbin (Bing), Mr. CHAN Peng Kuan and Ms. NI Hong as independent non-executive directors.*